ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Core Insights - The combination of ALX Oncology's investigational CD47-blocker, evorpacept, with rituximab and lenalidomide has shown promising anti-tumor activity and was well-tolerated in patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma [1][4] - The trial reported a complete response (CR) rate of 83% in patients with indolent NHL, significantly higher than the historical CR rate of 34% with rituximab alone [1][3] - The ongoing Phase 2 trial in previously untreated indolent NHL has completed enrollment, indicating continued evaluation of evorpacept's efficacy [1][4] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with evorpacept as its lead candidate [7] - The company aims to address significant unmet needs in cancer treatment by enhancing the therapeutic benefits of existing anti-cancer antibodies [4][7] Clinical Trial Details - The Phase 1/2 trial enrolled 20 patients, with 18 having indolent and 2 having aggressive R/R B-NHL, all of whom had previously received anti-CD20 monoclonal antibodies [2] - Evorpacept was administered at two dose levels, and the treatment was well-tolerated with no dose-limiting toxicities reported [2] - After a median follow-up of 28 months, the two-year progression-free survival (PFS) rate was 69% and the overall survival (OS) rate was 84% [3] Upcoming Presentation - Final results from the Phase 1 trial will be presented at the AACR 2025 Annual Meeting on April 29, 2025, highlighting the clinical research findings [5][6]